Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 96

1.

Limitations of non-invasive tests for assessment of liver fibrosis.

Patel K, Sebastiani G.

JHEP Rep. 2020 Jan 20;2(2):100067. doi: 10.1016/j.jhepr.2020.100067. eCollection 2020 Apr. Review.

2.

Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial.

Patel K, Harrison SA, Elkashab M, Trotter JF, Herring R, Rojter S, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane E, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M.

Hepatology. 2020 Mar 1. doi: 10.1002/hep.31205. [Epub ahead of print]

PMID:
32115759
3.

Editorial: blood biomarkers for advanced liver fibrosis in non-alcoholic fatty liver disease-not a simple choice?

Neil Guha I, Patel K.

Aliment Pharmacol Ther. 2020 Jan;51(1):179-180. doi: 10.1111/apt.15578. No abstract available.

PMID:
31850556
4.

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ; REGENERATE Study Investigators.

Lancet. 2019 Dec 14;394(10215):2184-2196. doi: 10.1016/S0140-6736(19)33041-7. Epub 2019 Dec 5.

PMID:
31813633
5.

Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox.

Satapathy SK, Jiang Y, Agbim U, Wu C, Bernstein DE, Teperman LW, Kedia SK, Aithal GP, Bhamidimarri KR, Duseja A, Maiwall R, Maliakkal B, Jalal P, Patel K, Puri P, Ravinuthala R, Wong VW, Abdelmalek MF, Ahmed A, Thuluvath PJ, Singal AK; Global NAFLD Consortium.

Liver Transpl. 2020 Jan;26(1):68-79. doi: 10.1002/lt.25672.

PMID:
31665561
6.

Reply.

Choi HSJ, Brouwer WP, Hansen BE, Janssen HLA, Patel K.

Hepatology. 2020 Feb;71(2):769. doi: 10.1002/hep.30980. Epub 2020 Jan 28. No abstract available.

PMID:
31593309
7.

Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B.

Choi HSJ, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, Janssen HLA, Patel K.

Hepatology. 2020 Feb;71(2):539-548. doi: 10.1002/hep.30857. Epub 2019 Oct 17.

PMID:
31309589
8.

Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B.

Di Bisceglie AM, King WC, Lisker-Melman M, Khalili M, Belle SH, Feld JJ, Ghany MG, Janssen HLA, Lau D, Lee WM, Ling SC, Cooper S, Rosenthal P, Schwarz KB, Sterling RK, Teckman JH, Terrault N; Hepatitis B Research Network (HBRN).

J Viral Hepat. 2019 Jul;26(7):856-865. doi: 10.1111/jvh.13104. Epub 2019 May 2.

PMID:
30974509
9.

Reply.

Galvin Z, Patel K, Bhat M.

Liver Transpl. 2019 Jun;25(6):969-970. doi: 10.1002/lt.25465. Epub 2019 Apr 29. No abstract available.

PMID:
30947397
10.

Noninvasive Predictors of High-Risk Varices in Patients with Non-Cirrhotic Portal Hypertension.

Cunningham ME, Parastandeh-Chehr G, Cerocchi O, Wong DK, Patel K.

Can J Gastroenterol Hepatol. 2019 Feb 7;2019:1808797. doi: 10.1155/2019/1808797. eCollection 2019.

11.

Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus-Related Acute Liver Failure.

Ajmera V, Huang H, Dao D, Feld JJ, Lau DT, Patel K, Rule JA, Daly M, Lee WM, Chung RT.

Cell Mol Gastroenterol Hepatol. 2019;7(2):477-479.e4. doi: 10.1016/j.jcmgh.2018.09.018. Epub 2018 Oct 17. No abstract available.

12.

Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.

Brahmania M, Lombardero M, Hansen BE, Terrault NA, Lok AS, Perrillo RP, Belle SH, Di Bisceglie AM, Feld JJ, Lee WM, Fried MW, Janssen HLA; Hepatitis B Research Network.

Clin Gastroenterol Hepatol. 2019 Nov;17(12):2541-2551.e2. doi: 10.1016/j.cgh.2019.02.005. Epub 2019 Feb 8.

13.

Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.

Galvin Z, Rajakumar R, Chen E, Adeyi O, Selzner M, Grant D, Sapisochin G, Greig P, Cattral M, McGilvray I, Ghanekar A, Selzner N, Lilly L, Patel K, Bhat M.

Liver Transpl. 2019 Jan;25(1):56-67. doi: 10.1002/lt.25338.

14.

Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Glass O, Henao R, Patel K, Guy CD, Gruss HJ, Syn WK, Moylan CA, Streilein R, Hall R, Mae Diehl A, Abdelmalek MF.

Hepatol Commun. 2018 Sep 21;2(11):1344-1355. doi: 10.1002/hep4.1237. eCollection 2018 Nov.

15.

Assessment of liver fibrosis progression and regression by a serological collagen turnover profile.

Karsdal MA, Hjuler ST, Luo Y, Rasmussen DGK, Nielsen MJ, Holm Nielsen S, Leeming DJ, Goodman Z, Arch RH, Patel K, Schuppan D.

Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G25-G31. doi: 10.1152/ajpgi.00158.2018. Epub 2018 Aug 30.

16.

Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma.

Kotha S, Neong S, Patel K.

Expert Rev Mol Diagn. 2018 Aug;18(8):713-722. doi: 10.1080/14737159.2018.1496020. Epub 2018 Jul 18.

PMID:
30019978
17.

Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B.

Khalili M, Shuhart MC, Lombardero M, Feld JJ, Kleiner DE, Chung RT, Terrault NA, Lisker-Melman M, Sanyal A, Lok AS; Hepatitis B Research Network (HBRN); Harvard Consortium.

Diabetes Care. 2018 Jun;41(6):1251-1259. doi: 10.2337/dc18-0040. Epub 2018 Mar 29.

18.

Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.

Younossi ZM, Stepanova M, Asselah T, Foster G, Patel K, Bräu N, Swain M, Tran T, Esteban R, Colombo M, Pianko S, Henry L, Bourliere M.

Clin Infect Dis. 2018 May 17;66(11):1742-1750. doi: 10.1093/cid/cix1106.

PMID:
29272349
19.

Systematic integrative analysis of gene expression identifies HNF4A as the central gene in pathogenesis of non-alcoholic steatohepatitis.

Baciu C, Pasini E, Angeli M, Schwenger K, Afrin J, Humar A, Fischer S, Patel K, Allard J, Bhat M.

PLoS One. 2017 Dec 7;12(12):e0189223. doi: 10.1371/journal.pone.0189223. eCollection 2017.

20.

Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment.

Lok AS, Ganova-Raeva L, Cloonan Y, Punkova L, Lin HS, Lee WM, Ghany MG; Hepatitis B Research Network (HBRN).

J Viral Hepat. 2017 Nov;24(11):1032-1042. doi: 10.1111/jvh.12732. Epub 2017 Jul 3.

Supplemental Content

Loading ...
Support Center